NeuBase Therapeutics, Inc. NBSE NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

NeuBase Therapeutics, Inc. (NBSE) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 3 Buy, 3 Hold.

NBSE Analyst Ratings

Buy

Ratings

3 Buy

3 Hold

Based on 6 analysts giving stock ratings to NeuBase Therapeutics, Inc. in the past 3 months

Rating breakdown

Buy

3 50%

Hold

3 50%

50%

Buy

3 analysts

50%

Hold

3 analysts

Sell

0 analysts

People Also View

NAMS

NewAmsterdam Pharma Company N.V.

$34.01

-1.25%

GLUE

Monte Rosa Therapeutics, Inc.

$18.23

+4.17%

CGEM

Cullinan Oncology, Inc.

$14.95

+4.18%

CMPX

Compass Therapeutics, Inc.

$5.85

+7.54%

IMMX

Immix Biopharma, Inc.

YS Biopharma Co., Ltd.

$1.02

+9.68%

LABP

Landos Biopharma, Inc.

$22.93

+0.57%

NeuBase Therapeutics, Inc. NBSE NASDAQ

NBSE Analyst Ratings

People Also View

Get Undervalued Stock Alerts